Browse articles from EyeWorld.org related to AMD. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ New designations granted to investigational treatment for retinal dystrophies ➤ Status update on BLA for bevacizumab for treatment of retinal diseases ➤ Acquisition news ➤ ASCRS news and events
➤ FDA approves aceclidine-based drop for presbyopia ➤ Long-term data supports efficacy of continuous wet AMD treatment ➤ First patient dosed in trial for drug eluting lacrimal canaliculus plug ➤ Acquisition news ➤ ASCRS news and events
➤ Phase 3 results for preservative-free redness reliever ➤ Enrollment complete in Phase 3 pivotal program for wet AMD treatment ➤ Dry AMD Phase 3 trial completes enrollment ➤ Study: 24-month data confirm durability of dry eye procedural treatment ➤ Partnership and acquisition news ➤ ASCRS news and events
➤ Results from second Phase 3 pivotal trial for presbyopia drop ➤ Interim Phase 2 data presented on DME, wet AMD treatment ➤ Phase 2 trial to investigate oral DME treatment ➤ First patient dosed in investigational cell therapy for photoreceptor diseases ➤ Phase 1 trial begins for minimally invasive dry AMD treatment ➤ Acquisitions and other company news ➤ ASCRS news and events
➤ Proof-of-concept trial for intravitreal implant for glaucoma patients ➤ Phase 3 study evaluating intravitreal gene therapy for wet AMD ➤ New analysis shows differentiation of investigational glaucoma treatment ➤ IND studies to investigate gene therapy for dry AMD ➤ ASCRS news and events
➤ ASCRS EyeWorld Weekly: View the current issue ➤ Transepithelial crosslinking NDA submission accepted ➤ Fast Track designation granted to drop being investigated for night driving impairment due to visual disturbances ➤ First-in-human interventional study for gene therapy treating Leber congenital amaurosis 4 ➤ Positive outcomes observed for geographic atrophy drug ➤ Regenerative Medicine Advanced Therapy designation granted to stem cell therapy for dry AMD ➤ ASCRS news and events
➤ Investigational drug-eluting contact lens for glaucoma sees positive results ➤ First clinical-stage RNA-targeting therapy for nAMD ➤ PDUFA data extended for BLA for treatment of macular telangiectasia ➤ Three rare disease designations granted to investigational gene therapy treatments ➤ Partnership and acquisition news ➤ ASCRS news and events
➤ FDA authorizes first device treatment for dry AMD ➤ Fast track designation granted to retinopathy of prematurity prevention therapy ➤ Fluorescent hydrogel for cataract surgery ➤ ASCRS news and events
➤ Positive topline Phase 3 confirmatory trial results for transepithelial crosslinking ➤ 18-month data from first-in-human drug-eluting IOL ➤ New Phase 2 findings for investigational geographic atrophy treatment ➤ Study: long-term, low-dose antiviral treatment reduces risk for HZO patients ➤ Acquisition news ➤ ASCRS news and events
➤ FDA approves new ‘full range of vision’ IOL ➤ Imaging platform designed for patients in supine position receives FDA clearance ➤ Last patient dosed in Phase 3 study of non-IV, non-opioid sedation method ➤ Phase 2 study begins to assess neuropathic corneal pain treatment ➤ Plans to submit BLA for treatment of severe vision loss due to retinitis pigmentosa ➤ Research discovers protein related to AMD ➤ ASCRS news and events